Patil K, Mallya R. Genus Zanthoxylum as Sources of Drugs for Treatment of Tropical Parasitic Diseases.
Curr Drug Discov Technol 2022;
19:e040322201773. [PMID:
35249493 DOI:
10.2174/1570163819666220304203504]
[Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Revised: 12/08/2021] [Accepted: 12/21/2021] [Indexed: 11/22/2022]
Abstract
The tropical parasitic infections account to more than 2 billion infections and cause substantial morbidity and mortality, and accounts to several million deaths every year. Majorly parasitic infections in humans and animals are caused by protozoa and helminths. Chronic infections in host can cause retardation, impairment of cognitive skills, development in young children and weaken the immune system. The burden is felt to a greater extent in developing countries due to poverty, inaccessibility to medicines and resistance observed to drugs. Thus, human health continues to be severely harmed by parasitic infections. Medicinal plants have received much attention as alternative sources of drugs. Zanthoxylum genus has been used ethnobotanically as an antiparasitic agent and the phytoconstituents in Zanthoxylum, show wide variety of chemical substances with proven pharmacological actions such as alkaloids (isoquinolines and quinolines responsible for antitumor activity, antimalarial, antioxidant and antimicrobial actions), lignans, coumarins (antibacterial, antitumour, vasodilatory and anticoagulant activities), alkamide (strong insecticidal properties, anthelminthic, antitussive and analgesic anti antimalarial property). Therefore, this article is an attempt to review the existing literature that emphasizes on potential of genus Zanthoxylum as source of lead compounds for treatment of parasitic diseases.
Collapse